Transcutaneous Port for Continuous Duodenal Levodopa/Carbidopa Administration in Parkinson's Disease
2011 (English)In: Movement Disorders, ISSN 0885-3185, E-ISSN 1531-8257, Vol. 26, no 2, 331-334 p.Article in journal (Refereed) Published
Motor fluctuations in Parkinson's disease (PD) can be reduced by intraduodenal infusion of levodopa-carbidopa (Duodopa®) via percutaneous endoscopic gastrojejunostomy (PEG). We applied the transcutaneous soft-tissue anchored titanium port (T-port) in 15 PD patients with motor fluctuations; 7 Duodopa-naive (non-PEG), and 8 previously receiving Duodopa (former-PEG). Motor scores (UPDRS-III) and quality of life (QOL, PDQ-8) were assessed at baseline and 6 month follow-up. Six patients had local irritation shortly after implantation, persisting in one patient at 6 month follow-up, which led to explantation. After having finished the protocol, four T-ports were explanted in total. UPDRS-III and PDQ-8 scores improved moderately in the non-PEG patients, but remained similar in the former-PEG users. Two former-PEG users developed polyneuropathy. No obstructions, retractions, or leakages occurred. Technical and hygienic properties of the T-port were preferred by most patients. The T-port seems to be suitable for most PD patients qualifying for Duodopa therapy, although local infection may lead to explantation during longer-term follow-up.
Place, publisher, year, edition, pages
2011. Vol. 26, no 2, 331-334 p.
Parkinson's disease, duodopa, T-port
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-134134DOI: 10.1002/mds.23408ISI: 000288461800022PubMedID: 20960486OAI: oai:DiVA.org:uu-134134DiVA: diva2:371610